“The American Society for Gastrointestinal Endoscopy (ASGE) has released its updated “ASGE guideline on screening and surveillance of Barrett’s esophagus,” published in the September issue of GIE: Gastrointestinal Endoscopy.
The guideline aims to help clinicians understand the published literature and quality of available data on screening and surveillance in patients with Barrett’s esophagus; a precancerous condition for esophageal cancer (adenocarcinoma.) This document addresses several key clinical issues in this field, including the role and impact of screening and surveillance of Barrett’s esophagus. As with other types of cancer, identifying this precancerous condition and early changes of cancer provides the best chance of successful treatment and, ultimately, improves patient outcomes.
Several endoscopic procedures and related technologies are used to screen and monitor patients with known or suspected Barrett’s esophagus. If changes are found in the cells lining the esophagus, various endoscopic treatment approaches are available.
This guideline addresses the utility of advanced imaging and sampling modalities used during screening and surveillance endoscopic procedures and includes chromoendoscopy, confocal laser endomicroscopy, endoscopic ultrasound, wide-area transepithelial sampling (WATS) and others. Table 4 contains a summary of the recommendations.
The document complies with the standards of guideline development set forth by the Institute of Medicine for the creation of trustworthy guidelines and provides recommendations based on the GRADE framework.
“We are hopeful that this current information will help guide clinicians in using the growing array of tools and technologies available to us to diagnose and manage Barrett’s esophagus, which, in turn, has the potential to significantly impact patient outcomes,” said Sachin Wani, MD, FASGE, Chair of the ASGE Standards of Practice Committee.”
The full guideline is available here.
Learn the facts about esophageal cancer
-Esophageal cancer has increased over 700% and is considered one of the fastest growing cancer in the US.*
-Risk factors include:
- Gastroesophageal Reflux Disease (GERD, acid reflux, chronic heartburn),
- poor nutrition,
- tobacco use,
- excessive alcohol use,
- Barrett’s esophagus.
-As one of the deadliest cancers, esophageal cancer has an overall 5 year survival rate of only 19.2%.
-There are no routine or standard screenings to improve early detection of esophageal cancer.
-Symptoms often arise late, once the cancer is considered advanced or “distant” (spread to lymph nodes and other organs.)
-Stage IV esophageal cancer has a survival rate of only 4.8%.
-Despite these facts, esophageal cancer research is extremely underfunded.
To make a tax-deductible donation to The Salgi Esophageal Cancer Research Foundation, please visit: salgi.org/donate
Qumseya, B. et al. (2019) ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointestinal Endoscopy. doi.org/10.1016/j.gie.2019.05.012.
Content may be edited.
This post contains information from an article regarding recently published research and reflects the content of that research. It does not necessarily reflect the views or opinions of The Salgi Esophageal Cancer Research Foundation who cannot be held responsible for the accuracy of the data.
To read more esophageal cancer news, please visit: SALGI.org/news
Follow The Salgi Esophageal Cancer Research Foundation on Facebook: Facebook.com/SalgiFoundation
The Salgi Esophageal Cancer Research Foundation is a 501 (c) (3) non profit organization as recognized by the Internal Revenue Service.
Content found on Salgi.org is for informational purposes only. The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.